Flonoltinib Maleate (novel JAK inhibitor for myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-08 — A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis: Single-arm, open-label, multicenter trial enrolling ~64 patients with moderate-to-high risk MF refractory/relapsed/intolerant to prior JAK inhibitors; dosing assigned by baseline platelet count, oral once-daily on empty stomach until withdrawal criteria met (trial-early; results pending). (novelty: 4)
Open questions
Related
Contributing findings
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis
08-apr-2026
novelty 4
per-area 4
introduces